Alcon Completes Acquisition of Aerie Pharmaceuticals

Friday, November 25 2022 | 15 h 30 min | News

Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals (Aerie).

Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease. Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity to leverage Aerie’s existing research and development capabilities.

“As we welcome the Aerie team to Alcon, we look forward to leveraging our expanding commercial footprint and expertise to bring Rocklatan^® and Rhopressa^® to even more customers and their patients,” said David Endicott, CEO of Alcon.

The transaction complements Alcon’s expansion into the ophthalmic pharmaceutical space, including acquisitions of the exclusive U.S. commercialization rights for Simbrinza^® from Novartis in April 2021 and Eysuvis^® and Inveltys^® from Kala Pharmaceuticals, Inc. in May 2022.

Alcon intends to fully integrate Aerie into its business. As previously disclosed, the Company has used debt to fund the transaction for a total purchase consideration of approximately $930 million.

Click HERE for the full press release.